MMS Holdings Joins Decentralized Trials & Research Alliance (DTRA) as A Founding Member to Accelerate The Adoption of Patient-Focused
CANTON, Mich. (January 29, 2021) – MMS Holdings – an award-winning, data-focused CRO – joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized Trials & Research Alliance (DTRA),” which launched on December 10th, 2020, plans to unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices, and new technologies in decentralized clinical research.
“As a specialized data services and technologies provider, MMS will help guide the life sciences industry into an exciting future where decentralized trials and research help the world find treatments and cures at a more rapid pace,” said Eric Harvey, Director of Biostatistics and Data Science, MMS. “We believe that innovation and growth has a place in every part of our industry, and the proliferation of decentralized clinical trials is set to become one of the biggest changes that we’ve seen in industry in the past decade.”
“We are extremely gratified to welcome MMS to the Decentralized Trials & Research Alliance,” said Amir Kalali, MD, founder of several collaborative life science communities, and co-convenor of DTRA. “By advancing decentralized research we can make the clinical trial process more patient-focused, increase trial efficiency and encourage use of technologies. We are excited by MMS’ commitment to embracing decentralized trials and to changing the culture that has been the rate limiter to innovation.”
Experts estimate that COVID-19 may set back non-pandemic clinical trials by several years due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical investigators. Inclusion of representative patient populations in clinical trials by race, age and geographic location has long been an operational challenge. COVID-19 has amplified the disparities and inclusion biases that have become hurdles for potential trial participants.
“Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives – and by taking part in the DTRA, MMS is demonstrating its leadership to drive change,” said Craig Lipset, DTRA co-convener, clinical innovation advisor, and a pioneer in decentralized trials. “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, regulators, technology leaders and patient communities, we can remove remaining barriers to adoption and impact patients today.”
MMS joins with its peer DTRA Member organizations to provide expertise to identify and address gaps and needs and advance best practices through effective education and communication. MMS urges other organizations interested in taking part to visit DTRA.org.
The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.
MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for the last three consecutive years.
For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.
For further information please contact:
Lazar – Finn Partners
646 871 8485
For Non-media Inquiries: